Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re diving right into trading today with the biggest pre-market stock movers for Wednesday! Source: Eric Urquhart/Shutterstock.com Moving stocks this morning are clinical trials, ear...
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage cancer prevention diagnostics company, today...
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Lishan Aklog, Chairman and CEO, will partici...
Analyst comments factored heavily in Monday's midday action. InnovAge (NASDAQ:INNV) added to last week's losses following a downgrade, while Lucid Diagnostics (NASDAQ:LUCD) got a lift from a newly instated Buy rating. In other news, DiDi Global (NYSE:DIDI) suffered additional selling pressure...
Medical diagnostics company Lucid Diagnostics (NASDAQ:LUCD) has added ~8.9% in the pre-market on below-average volume after Ascendiant Capital began its coverage on the micro-cap stock with a $16 per share target to imply a premium of ~225.2% upside to Thursday’s close. About...
The shares of the company are extremely volatile as visibility into the financial future of the company is limited. However, we do think that, while certainly not devoid of risk, the shares potentially contain much more value, given Lucid's addressable market and the rapid build-up of...
Chronic heartburn patients in Phoenix, Denver, Salt Lake City, and Las Vegas can now request video telemedicine physician evaluation and referral for rapid, office-based EsoGuard testing to detect esophageal precancer before it progresses to deadly cancer Lucid Diagnostics...
Shares of Lucid Diagnostics (LUCD -18.9%) are down sharply today after the company reported that its Q3 2021 net loss widened ~244% to ~$7M (-$0.49 net loss per share, basic and diluted). Operating expenses increased ~225% to ~$6.6M. The company has just $200K in revenue for the quarter due t...
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Dennis McGrath, Chief Financial Offi...
Shares of PAVmed (NASDAQ:PAVM) are down 10% in after-hours trading after the company's Q3 2021 earnings results missed estimates on revenue, while EPS was in-line. On a non-GAAP basis, the company's net loss widened ~121% to ~$12.3M (-$0.10 per share adjusted). Operating expenses in...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Inc. Company Name:
LUCD Stock Symbol:
NASDAQ Market:
Lucid Diagnostics Inc. Website:
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...